Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15637196 | 0.80 | HSD11B1 (0.46) | HSD11B1ALDH1A1CYP2A6LMNA | |
| SCHEMBL3455954 | 0.79 | MYC (0.37) | ALDH1A1FGFR1CYP1A2CYP2A6 | |
| SCHEMBL8050739 | 0.76 | GRIA1 (0.36) | HSD11B1ALDH1A1SRCCYP1A2LMNA | |
| SCHEMBL19534945 | 0.71 | RAPGEF4 (0.31) | CYP1A2CYP2A6 | |
| SCHEMBL1144540 | 0.71 | — | — | |
| SCHEMBL4371389 | 0.68 | ESR2 (0.41) | HSD11B1ALDH1A1CYP2A6LMNA | |
| SCHEMBL1815221 | 0.67 | FGFR1 (0.33) | FGFR1SRCCYP1A2CYP2A6LMNA | |
| SCHEMBL2990875 | 0.67 | SRC (0.41) | ALDH1A1FGFR1SRCCYP1A2CYP2A6 | |
| SCHEMBL8734269 | 0.67 | ACHE (0.41) | FGFR1 | |
| SCHEMBL11405867 | 0.67 | PDK2 (0.34) | ALDH1A1CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197736-A1 | CETP ACTIVITY INHIBITORS | CETP, MTTP, CES1 | HSD11B1 51/4885ALDH1A1 3804/4885FGFR1 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.